In an analytical study comparing the efficacy of multiple ALK-TKIs in Asian ALK-positive NSCLC patients, ensartinib emerged as an efficient first-line treatment for Asian ALK-positive NSCLC patients (12). This evidence concerns the gene ALK and non-small cell lung carcinoma.